Caveat in Chinese trial was the increased symptomatic intracranial hemorrhage risk ...

In a multicenter randomized trial, tenecteplase did not improve vision recovery compared with aspirin when given within 4.5 hours of acute central retinal artery occlusion (CRAO). The ...

Healthcare providers are advised to stop using the devices, after a failure to detach was linked with four serious injuries and one death.

Global phase 3 OCEANIC-STROKE randomized 12,327 patients to asundexian 50 mg daily vs placebo on background antiplatelets, with follow-up to 31 months. Treatment effects were consistent across TOAST ...

Guidelines emphasize single-pill combinations and deprescribing strategies to combat polypharmacy and hyperpolypharmacy in ...

An investigational anti-clotting medication, asundexian, demonstrated a reduction in the risk of a second ischemic ...

Johnson & Johnson today announced 12-month pilot-phase data from the OMNY-AF study, evaluating the investigational OMNYPULSE Platform for the treatment of symptomatic paroxysmal atrial fibrillation ...